CANCER CARE THROUGH ARTIFICIAL INTELLIGENCE: PRESENT CAPABILITIES, CLINICAL INTEGRATION, AND FUTURE POTENTIAL - A REVIEW
Abstract
The role of Artificial Intelligence and Machine Learning is developing in an exponentially increasing manner in all respects of Human Life, especially in the health field. Ranging from imaging and pathology to genomics, treatment course planning, decision support in a clinical setting, discovery of drugs, and establishment of new parameters for trials, artificial intelligence has come a long way in all realms of oncology.
The promises and challenges in reality have been put forth by major prospective implementation and regulation in recent years. The requirements of validation and adoption of AI have been established in this critical analysis, which assimilates evidence not only towards efficient implementation but also towards familiarity with methodology, consideration with ethics, challenges with regulation, and assimilate major contributions in the developmental years. A major role in implementation and regulation can be established with convening a regulation and overlooking body concerning AI validity and during prosecution of ongoing clinical trials
References
1. Fountzilas, E., Pearce, T., Baysal, M.A. et al. Convergence of evolving artificial intelligence and machine learning techniques in precision oncology. npj Digit. Med. 8, 75 (2025).
2. Lotter W, et al. Artificial Intelligence (AI) in Oncology: Current Landscape. PMC (2024)
3. FDA De Novo Decision Summary — Paige Prostate (DEN200080). U.S. Food & Drug Administration. Decision date: Sep 21, 2021. (De Novo file & decision summary PDF
4. Lunit INSIGHT MMG — FDA 510(k) Premarket Notification (K211678). FDA access data summary (device description, predicate).
5. Paige.ai press release — FDA Breakthrough Device designation for Paige PanCancer Detect (Apr 3, 2025)
6. Wang X, et al. Deep Learning for Cancer Detection Based on Genomic and Imaging Data. (2025). PMC.
7. Cifci, D., et al. Artificial intelligence to identify genetic alterations in conventional histo... systematic review (2017–2021).
8. Park, S.H., et al. Randomized Clinical Trials of Artificial Intelligence in ... (2022). PMC review of AI randomized trials
9. Collins, G.S., et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ 2024
10. Reuters / FDA qualification of AIM-NASH (2025) — example of AI tool qualified for drug development in adjacent domain
11. Rehman, M.H., et al. Federated learning for medical imaging (2023). PMC review.
12. Guan, H., et al. Federated learning for medical image analysis: A survey (2024). ScienceDirect survey
13. BMJ 2024;385:e078378
14. FDA De Novo Decision Summary — Paige Prostate (DEN200080). U.S. Food & Drug Administration. Decision date: Sep 21, 2021.
15. The Pathologist. Cancer Diagnostics in the Age of AI. Sep 2024. (Contextual reporting on pathology AI
16. Olawade DB, et al. Integrating AI into Cancer Immunotherapy—A Narrative Review. MDPI (2025)
17. NHS / media reporting on large-scale AI screening trial — coverage (2025). Reports on NHS launching large breast imaging AI trial)
18. Stetson, P.D., Choy, J., Summerville, N. et al. Responsible Artificial Intelligence governance in oncology. npj Digit. Med. 8, 407 (2025). https://doi.org/10.1038/s41746-025-01794-w
19. Huhulea EN, et al. Artificial Intelligence Advancements in Oncology: A Review. (2025). PMID/PMC
20. IntuitionLabs. AI Medical Devices: 2025 Status, Regulation & Challenges. (Oct/Nov 2025)
21. Reuters. US FDA qualifies first AI tool to help speed liver disease drug development. (Dec 2025) — AIM-NASH qualification
22. November 7, 2025. doi:10.1001/jamanetworkopen.2025.42338
